{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:08:23Z","timestamp":1792793303476,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.eprac.2024.12.012","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T11:38:45Z","timestamp":1734435525000},"page":"536-546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Management Aspects of Medical Therapy in Graves Disease"],"prefix":"10.1016","volume":"31","author":[{"given":"Rutu","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha E.","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8984-3079","authenticated-orcid":false,"given":"Sina","family":"Jasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2024.12.012_bib1","series-title":"StatPearls","article-title":"Graves disease","author":"Pokhrel","year":"2024"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.012_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101387","article-title":"Graves\u2019 disease: epidemiology, genetic and environmental risk factors and viruses","volume":"34","author":"Antonelli","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2024.12.012_bib3","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1210\/clinem\/dgae222","article-title":"A\u00a02023 international survey of clinical practice patterns in the management of Graves disease: a decade of change","volume":"109","author":"Villagelin","year":"2024","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.012_bib4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4158\/EP.1.3.193","article-title":"The medical management of Graves\u2019 disease","volume":"1","author":"Ross","year":"1995","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2024.12.012_bib5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.micpath.2018.01.004","article-title":"Infections, genetic and environmental factors in pathogenesis of autoimmune thyroid diseases","volume":"116","author":"Shukla","year":"2018","journal-title":"Microb Pathog"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.012_bib6","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/ICU.0000000000000529","article-title":"Thyroid eye disease: what is new to know?","volume":"29","author":"Li","year":"2018","journal-title":"Curr Opin Ophthalmol"},{"issue":"12","key":"10.1016\/j.eprac.2024.12.012_bib7","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","article-title":"Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway","volume":"170","author":"Pritchard","year":"2003","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.012_bib8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/cen.14296","article-title":"Prevalence of thyroid eye disease in Graves\u2019 disease: a meta-analysis and systematic review","volume":"93","author":"Chin","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.012_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-199401000-00001","article-title":"Dermopathy of Graves disease (pretibial myxedema). review of 150 cases","volume":"73","author":"Fatourechi","year":"1994","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.eprac.2024.12.012_bib10","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40618-014-0157-7","article-title":"Thymic hyperplasia in patients with Graves\u2019 disease","volume":"37","author":"Dalla","year":"2014","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.012_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4103\/ijem.ijem_137_21","article-title":"Rapid differential diagnosis of thyrotoxicosis using T3\/T4 ratio, FT3\/FT4 ratio and color Doppler of thyroid gland","volume":"25","author":"Narkar","year":"2021","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.012_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1530\/EJE-07-0450","article-title":"TSH-receptor autoimmunity in Graves\u2019 disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study","volume":"158","author":"Laurberg","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"4S suppl 1","key":"10.1016\/j.eprac.2024.12.012_bib13","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/IOP.0000000000001052","article-title":"Thyrotropin receptor antibodies-an overview","volume":"34","author":"Kotwal","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.eprac.2024.12.012_bib14","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgae448","article-title":"US-based, prospective, blinded study of thyrotropin receptor antibody in autoimmune thyroid disease","author":"Lupo","year":"2024","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.012_bib15","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/a-2021-0596","article-title":"Comparison between thyroid stimulating immunoglobulin and TSH-receptor antibodies in the management of Graves\u2019 orbitopathy","volume":"131","author":"Khamisi","year":"2023","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"7","key":"10.1016\/j.eprac.2024.12.012_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0270890","article-title":"Anti-TSH receptor antibodies (TRAb): comparison of two third generation automated immunoassays broadly used in clinical laboratories and results interpretation","volume":"17","author":"L\u00f3pez Ortega","year":"2022","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.012_bib17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.14366\/usg.18037","article-title":"Ultrasound elastography of the thyroid: principles and current status","volume":"38","author":"Zhao","year":"2019","journal-title":"Ultrasonography"},{"issue":"6232","key":"10.1016\/j.eprac.2024.12.012_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/bmj.281.6232.24","article-title":"D-propranolol and DL-propranolol both decrease conversion of L-thyroxine to L-triiodothyronine","volume":"281","author":"Heyma","year":"1980","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.012_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2265.1983.tb03196.x","article-title":"Different effects of propranolol, alprenolol, sotalol, atenolol and metoprolol on serum T3 and serum rT3 in hyperthyroidism","volume":"18","author":"Perrild","year":"1983","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"10.1016\/j.eprac.2024.12.012_bib20","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.012_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association guideline for the management of Graves\u2019 hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.eprac.2024.12.012_bib22","series-title":"StatPearls","article-title":"Beta blockers","author":"Farzam","year":"2024"},{"issue":"5","key":"10.1016\/j.eprac.2024.12.012_bib23","doi-asserted-by":"crossref","first-page":"R261","DOI":"10.1530\/EJE-18-0678","article-title":"ANNIVERSARY REVIEW: antithyroid drug therapy: 70 years later","volume":"179","author":"Burch","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.012_bib24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2265.2001.01239.x","article-title":"Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism","volume":"54","author":"Homsanit","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"10.1016\/j.eprac.2024.12.012_bib25","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1210\/jc.2003-030185","article-title":"Antithyroid drugs in the management of patients with Graves\u2019 disease: an evidence-based approach to therapeutic controversies","volume":"88","author":"Cooper","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2024.12.012_bib26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fendo.2020.00286","article-title":"Pharmacodynamic response to anti-thyroid drugs in Graves\u2019 hyperthyroidism","volume":"11","author":"Abbara","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.eprac.2024.12.012_bib27","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/archinte.1990.00390170124027","article-title":"Effect of abnormal thyroid function on the severity of Graves\u2019 ophthalmopathy","volume":"150","author":"Prummel","year":"1990","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.eprac.2024.12.012_bib28","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1089\/thy.2016.0652","article-title":"Long-term antithyroid drug treatment: a systematic review and meta-analysis","volume":"27","author":"Azizi","year":"2017","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.012_bib29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12902-020-00670-w","article-title":"Control of Graves\u2019 hyperthyroidism with very long-term methimazole treatment: a clinical trial","volume":"21","author":"Azizi","year":"2021","journal-title":"BMC Endocr Disord"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.012_bib30","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/thy.2008.0364","article-title":"Methimazole-induced agranulocytosis in patients with Graves\u2019 disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily","volume":"19","author":"Takata","year":"2009","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.012_bib31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/archinte.1990.00390150107020","article-title":"Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring","volume":"150","author":"Tajiri","year":"1990","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1016\/j.eprac.2024.12.012_bib32","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1210\/jc.2013-2569","article-title":"Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan","volume":"98","author":"Nakamura","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.012_bib33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S2213-8587(20)30025-5","article-title":"Methimazole and risk of acute pancreatitis","volume":"8","author":"Brix","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.eprac.2024.12.012_bib34","doi-asserted-by":"crossref","first-page":"e4527","DOI":"10.1210\/clinem\/dgaa544","article-title":"Methimazole treatment and risk of acute pancreatitis: a population-based cohort study","volume":"105","author":"Pecere","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.eprac.2024.12.012_bib35","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra042972","article-title":"Antithyroid drugs","volume":"352","author":"Cooper","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.012_bib36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/thy.2006.16.295","volume":"16","author":"Carella","year":"2006","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.eprac.2024.12.012_bib37","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1055\/s-0035-1555759","article-title":"Outcome Prediction of treatment of Graves\u2019 hyperthyroidism with antithyroid drugs","volume":"47","author":"Piantanida","year":"2015","journal-title":"Horm Metab Res"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.012_bib38","doi-asserted-by":"crossref","DOI":"10.20945\/2359-3997000000609","article-title":"Prediction for recurrence following antithyroid drug therapy for Graves\u2019 hyperthyroidism","volume":"67","author":"Weng","year":"2023","journal-title":"Arch Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2024.12.012_bib39","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1532-5415.1994.tb04973.x","article-title":"Age-related therapeutic response to antithyroid drug in patients with hyperthyroid Graves\u2019 disease","volume":"42","author":"Yamada","year":"1994","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.012_bib40","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1210\/jc.2015-3644","article-title":"Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves\u2019 hyperthyroidism","volume":"101","author":"Vos","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.012_bib41","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1530\/EJE-16-0986","article-title":"External validation of the GREAT score to predict relapse risk in Graves\u2019 disease: results from a multicenter, retrospective study with 741 patients","volume":"176","author":"Struja","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2024.12.012_bib42","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1055\/a-0974-3991","article-title":"External validation of the GREAT score in Turkish patients with Graves\u02bc hyperthyroidism treated with the titration regimen method of antithyroid drugs: a multicenter study","volume":"51","author":"Zuhur","year":"2019","journal-title":"Horm Metab Res"},{"issue":"12","key":"10.1016\/j.eprac.2024.12.012_bib43","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s40618-018-0918-9","article-title":"Antithyroid drug treatment for Graves\u2019 disease: baseline predictive models of relapse after treatment for a patient-tailored management","volume":"41","author":"Masiello","year":"2018","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"10","key":"10.1016\/j.eprac.2024.12.012_bib44","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s40618-024-02358-7","article-title":"The need for the GREAT+ score to predict relapse in Graves\u2019 disease: a questionnaire among patients and internal medicine specialists","volume":"47","author":"Jansen","year":"2024","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.012_bib45","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s12020-023-03656-5","article-title":"Risk of recurrence at the time of withdrawal of short- or long-term methimazole therapy in patients with Graves\u2019 hyperthyroidism: a randomized trial and a risk-scoring model","volume":"84","author":"Azizi","year":"2024","journal-title":"Endocrine"},{"issue":"8","key":"10.1016\/j.eprac.2024.12.012_bib46","first-page":"477","article-title":"Long-term continuous methimazole or radioiodine treatment for hyperthyroidism","volume":"15","author":"Azizi","year":"2012","journal-title":"Arch Iran Med"},{"issue":"12","key":"10.1016\/j.eprac.2024.12.012_bib47","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1089\/thy.2015.0195","article-title":"Outcomes in relapsed Graves\u2019 disease patients following radioiodine or prolonged low dose of methimazole treatment","volume":"25","author":"Villagelin","year":"2015","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.eprac.2024.12.012_bib48","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1089\/thy.2019.0180","article-title":"Increased remission rates after long-term methimazole therapy in patients with Graves\u2019 disease: results of a randomized clinical trial","volume":"29","author":"Azizi","year":"2019","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.012_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101631","article-title":"Long-term thionamide antithyroid treatment of Graves\u2019 disease","volume":"37","author":"Azizi","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eprac.2024.12.012_bib50","doi-asserted-by":"crossref","first-page":"e1881","DOI":"10.1210\/clinem\/dgae456","article-title":"Approach to the patient considering long-term antithyroid drug therapy for Graves\u2019 disease","volume":"109","author":"Azizi","year":"2024","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2024.12.012_bib51","article-title":"Interventions for hyperthyroidism pre-pregnancy and during pregnancy","author":"Earl","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.012_bib52","first-page":"946","article-title":"Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism","volume":"84","author":"Millar","year":"1994","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.012_bib53","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00404-010-1362-z","article-title":"Outcomes of pregnancy complicated with hyperthyroidism: a cohort study","volume":"283","author":"Luewan","year":"2011","journal-title":"Arch Gynecol Obstet"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.012_bib54","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ecl.2024.05.002","article-title":"Evaluation and management of thyrotoxicosis during pregnancy","volume":"53","author":"Haridas","year":"2024","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.012_bib55","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/thy.2016.0457","article-title":"2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum","volume":"27","author":"Alexander","year":"2017","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.012_bib56","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2265.1984.tb00119.x","article-title":"Maternal hyperthyroidism and congenital malformation in the offspring","volume":"20","author":"Momotani","year":"1984","journal-title":"Clin Endocrinol\u00a0(Oxf)"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.012_bib57","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S2213-8587(13)70086-X","article-title":"Hyperthyroidism in pregnancy","volume":"1","author":"Cooper","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.012_bib58","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40842-018-0054-7","article-title":"Graves\u2019 hyperthyroidism in pregnancy: a clinical review","volume":"4","author":"Nguyen","year":"2018","journal-title":"Clin Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.012_bib59","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.1097\/AOG.0000000000003893","article-title":"Thyroid disease in pregnancy: ACOG Practice Bulletin, number 223","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.eprac.2024.12.012_bib60","first-page":"477","article-title":"The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmstead County, Minnesota","volume":"92","author":"Bartley","year":"1994","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.012_bib61","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ecl.2021.12.004","article-title":"2022 update on clinical management of Graves disease and thyroid eye disease","volume":"51","author":"Hoang","year":"2022","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.eprac.2024.12.012_bib62","series-title":"StatPearls [Internet]","article-title":"Thyroid eye disease","author":"Shah","year":"2023"},{"issue":"20","key":"10.1016\/j.eprac.2024.12.012_bib63","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves\u2019 orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.eprac.2024.12.012_bib64","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.012_bib65","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2024.12.012_bib66","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1210\/clinem\/dgab070","article-title":"Statins decrease the risk of orbitopathy in newly diagnosed patients with Graves disease","volume":"106","author":"Nilsson","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2024.12.012_bib67","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-8587(21)00238-2","article-title":"Statins for Graves\u2019 orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial","volume":"9","author":"Lanzolla","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.012_bib68","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12020-023-03680-5","article-title":"Statins and thyroid eye disease (TED): a systematic review","volume":"85","author":"Malboosbaf","year":"2024","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.eprac.2024.12.012_bib69","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"Taylor","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.012_bib70","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/cen.14997","article-title":"Changes in thyroid function and evolution of subclinical thyroid disease in older men","volume":"100","author":"Tan","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.012_bib71","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2265.2010.03908.x","article-title":"Subclinical thyrotoxicosis in an outpatient population\u2014predictors of outcome","volume":"74","author":"Schouten","year":"2011","journal-title":"Clin Endocrinol\u00a0(Oxf)"},{"issue":"25","key":"10.1016\/j.eprac.2024.12.012_bib72","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMcp1709318","article-title":"Subclinical hyperthyroidism","volume":"378","author":"Biondi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.012_bib73","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2265.2012.04345.x","article-title":"Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism","volume":"77","author":"Das","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.012_bib74","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/thy.2020.0433","article-title":"Treatment of subclinical hyperthyroidism in the elderly: comparison of radioiodine and long-term methimazole treatment","volume":"31","author":"Azizi","year":"2021","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.012_bib75","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/17446651.2023.2167709","article-title":"Non-thionamide antithyroid drug options in Graves\u2019 hyperthyroidism","volume":"18","author":"Ruslan","year":"2023","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"1-3","key":"10.1016\/j.eprac.2024.12.012_bib76","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12020-008-9107-5","article-title":"Low doses of cholestyramine in the treatment of hyperthyroidism","volume":"34","author":"Kaykhaei","year":"2008","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.012_bib77","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3803\/EnM.2016.31.3.476","article-title":"Cholestyramine use for rapid reversion to euthyroid states in patients with thyrotoxicosis","volume":"31","author":"Ha","year":"2016","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"4","key":"10.1016\/j.eprac.2024.12.012_bib78","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.8655","article-title":"Comparison of propylthiouracil vs methimazole for thyroid storm in critically ill patients","volume":"6","author":"Lee","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.012_bib79","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1097\/SLA.0000000000003580","article-title":"The American Association of Endocrine Surgeons guidelines for the definitive surgical management of thyroid disease in adults","volume":"271","author":"Patel","year":"2020","journal-title":"Ann Surg"},{"issue":"10428","key":"10.1016\/j.eprac.2024.12.012_bib80","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(23)02016-0","article-title":"Hyperthyroidism","volume":"403","author":"Chaker","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.012_bib81","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00268-015-3298-8","article-title":"Effectiveness and mechanism of preoperative lugol solution for reducing thyroid blood flow in patients with euthyroid Graves\u2019 disease","volume":"40","author":"Huang","year":"2016","journal-title":"World J Surg"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.012_bib82","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1210\/jc.2007-0229","article-title":"Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves\u2019 disease","volume":"92","author":"Erbil","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2024.12.012_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1234056","article-title":"Preoperative preparation for Graves\u2019 disease","volume":"14","author":"Xu","year":"2023","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2024.12.012_bib84","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1210\/jc.2003-031981","article-title":"Rapid preoperative preparation for severe hyperthyroid Graves\u2019 disease","volume":"89","author":"Panzer","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.012_bib85","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s12020-018-1661-x","article-title":"Therapeutic plasmapheresis in thyrotoxic patients","volume":"62","author":"Simsir","year":"2018","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.012_bib86","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MOH.0000000000000534","article-title":"The 2019 guidelines from the American Society for Apheresis: what\u2019s new?","volume":"26","author":"Connelly-Smith","year":"2019","journal-title":"Curr Opin Hematol"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.012_bib87","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4183\/aeb.2016.291","article-title":"Is there a relationship between vitamin D status and hypocalcemia after total thyroidectomy?","volume":"12","author":"Da\u011flar","year":"2016","journal-title":"Acta Endocrinol (Buchar)"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.012_bib88","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1136\/jim-2020-001644","article-title":"Preoperative vitamin D deficiency is associated with increased risk of postoperative hypocalcemia after total thyroidectomy","volume":"69","author":"Choi","year":"2021","journal-title":"J\u00a0Investig Med"},{"issue":"2","key":"10.1016\/j.eprac.2024.12.012_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100415","article-title":"The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study","volume":"7","author":"Izawa","year":"2022","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.eprac.2024.12.012_bib90","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1007\/s10238-023-01082-5","article-title":"Immune-related thyroid dysfunctions during anti PD-1\/PD-L1 inhibitors: new evidence from a single centre experience","volume":"23","author":"Nervo","year":"2023","journal-title":"Clin Exp Med"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.012_bib91","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12902-020-00613-5","article-title":"New-onset Graves\u2019 disease after the initiation of nivolumab therapy for gastric cancer: a case report","volume":"20","author":"Yamada","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.012_bib92","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12020-024-03718-2","article-title":"Thyroid disorders induced by immune checkpoint inhibitors","volume":"85","author":"Karaviti","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.eprac.2024.12.012_bib93","article-title":"A\u00a0case report of Graves\u2019 disease induced by the anti-human programmed cell death-1 monoclonal antibody pembrolizumab in a bladder cancer patient","volume":"2019","author":"Yajima","year":"2019","journal-title":"Case Rep Endocrinol"},{"key":"10.1016\/j.eprac.2024.12.012_bib94","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3389\/fendo.2018.00813","article-title":"Nivolumab induced thyroid dysfunction: unusual clinical presentation and challenging diagnosis","volume":"9","author":"Iadarola","year":"2019","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2024.12.012_bib95","article-title":"Treatment of ipilimumab induced Graves\u2019 disease in a patient with metastatic melanoma","volume":"2016","author":"Azmat","year":"2016","journal-title":"Case Rep Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2024.12.012_bib96","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000464285","article-title":"Tremelimumab-induced Graves hyperthyroidism","volume":"6","author":"Gan","year":"2017","journal-title":"Eur Thyroid J"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.012_bib97","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/01676830.2014.949792","article-title":"Thyroid-like ophthalmopathy in a euthyroid patient receiving ipilimumab","volume":"33","author":"McElnea","year":"2014","journal-title":"Orbit"},{"key":"10.1016\/j.eprac.2024.12.012_bib98","article-title":"A\u00a0novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis","volume":"2015","author":"Yu","year":"2015","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"17","key":"10.1016\/j.eprac.2024.12.012_bib99","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2024.12.012_bib100","first-page":"4254","article-title":"Sequential occurrence of thyroid autoantibodies and Graves\u2019 disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients","volume":"85","author":"Jubault","year":"2000","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2024.12.012_bib101","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1210\/endrev\/bnaa022","article-title":"New therapeutic horizons for Graves\u2019 hyperthyroidism","volume":"41","author":"Lane","year":"2020","journal-title":"Endocr Rev"},{"key":"10.1016\/j.eprac.2024.12.012_bib102","article-title":"Effects of low-dose methotrexate with MMI in patients with Graves\u2019 disease: results of a randomized clinical trial","author":"Xie","year":"2024","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2400870X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2400870X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:42:21Z","timestamp":1744702941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2400870X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1530891X2400870X"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.12.012","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management Aspects of Medical Therapy in Graves Disease","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}